Let's Get Started

Featured

Will AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) Patent News Trigger Further Rally?

Will AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) Patent News Trigger Further Rally?

Jan 18, 2023

AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) stock is flying with a price-volume breakout!!

It was hardly a surprise that the AgriFORCE Growing Systems Ltd (NASDAQ:AGRI) stock went on a major really yesterday and ended up hitting a four-month high following a jump of 29% and closed at a 4-month high. Considering the magnitude of the gains, investors are expected to be in hot pursuit over the course of the coming days.

Why Such a Big Rally?

The news that triggered the rally in the stock was the award of the patent for its proprietary method for the natural processing and modification of gains by the United States Patent and Trademark Office.

AgriFORCE Growing Systems Company Summary

Company Name: AgriFORCE Growing Systems Ltd.

Ticker: AGRI

Exchange: NASDAQ

Website: https://agriforcegs.com/

AgriFORCE Growing Systems Company Summary:

AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI; AGRIW) is an agtech company focused on building an integrated agtech platform that combines the best technology, intellectual property, and knowledge to solve an urgent problem – providing the best solutions to help drive sustainable crops and nutritious food for people around the world.

The AgriFORCE vision is to be a global leader in delivering plant-based foods and products through an advanced and sustainable agtech platform that makes a positive change in the world—from seed to table. Additional information about AgriFORCE is available at: www.agriforcegs.com.

#1 – AgriFORCE Granted Patent Related to its Proprietary Methods for Processing Nutritious Foods Under the UN(THINK)™ Foods Brand

The company is highly innovative and is engaged in the advancement of agricultural technology which could promote sustainable agriculture as well as crop processing operations.

By way of this particular process, it would be possible to turn grains of rice, pulses, and other seeds into fiber-rich, high-protein, and low-starch baking flour products. It is clear to see that it is a patent that could lead to a revolution in the fast-growing nutritious foods space.

It ought to be noted that the unique process had been acquired by AgriFORCE through the acquisition of Manna International Group back in May last year. The acquisition was part of the company’s overall aggressive acquisition strategy and it seems it may have paid off handsomely following the award of the patent.

#2 – AGRI stock Trades Above 20-Day and 50-Day EMA

Tuesday’s big rally has pushed the stock above key moving averages – signaling a short-term momentum trade. The stock is now trading well above the 20-Day and 50-Day EMA of $1.20 and $1.15 respectively.

Moreover, the stock closed at a 4-month high triggering a multi-month price-volume breakout.

#3- Growth Through Acquisition – Delphy Group’s Acquisition In Focus

Last month on December 28 the company announced that it had got shareholder approval for the acquisition of Delphy Group, which is expected to help AgriFORCE in offering its products in the global market easily.

The acquisition is expected to be closed at some point in the coming weeks. The company has also stated that throughout the course of 2023, it expects to witness certain developments which could further accelerate its growth. AgriFORCE remains committed to its aggressive merger and acquisition strategy.

The company said that ” We will continue to drive our M&A strategy to further strengthen our AgTech 2.0 platform.”

#4 Impressive Outlook

The company is projected to bring the first products under UN(THINK) Foods to market. In particular, with the B2B and direct-to-consumer launch of Awakened Flour, and hope to create a new standard for sprouted flours.

Following this, the company plan to launch our Power Flour which will bring superior nutrition with no compromise to consumers. Additionally, they have several other consumer products in the pipeline, for which we intend to provide additional details in 2023.

Moreover, AgriFORCE will start advancing the expansion of Delphy into North America as well as continue to build our Delphy Digital platform and suite of services.

The company noted ” As we look ahead, we believe we have secured the foundational pieces to transform our business in the near term. We believe 2023 will be a pivotal year in the company’s history and that we have laid the foundation in 2022 to achieve major achievements and successes in the coming year.”

read more
Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!

Sharps Technology, Inc. (NASDAQ: STSS) Has An Accelerated Near-Term Path Product For The Commercialization & Accelerated Revenue Growth!

Jan 11, 2023

With An Accelerated Near-Term Path For Product Commercialization And Expanded Manufacturing Capacity, Sharps Technology, Inc. (NASDAQ: STSS) Will Have The Ability To Support The Industry With Innovative, Market Leading Injectable Drug Delivery Solutions And Accelerate A Path Towards Revenue Growth.

STSS
Sharps Technology, Inc. (NASDAQ: STSS)

Newly NASDAQ-traded Sharps Technology, Inc. (NASDAQ: STSS) offers innovative injectable syringe solutions to a global healthcare crisis that is not being talked about nearly enough.

  • Most syringes waste a significant amount of injectable medicine which is thrown away with the used needle/syringe.

  • This adds cost and reduces the availability of life-saving injectable drugs for us all. Whether we are looking at a pandemic response, hard-to-manufacture drug products, or managing long-term chronic illness, we can’t afford to waste this precious supply.

  • The problem is sufficiently worrisome that the Federal Government is passing new legislation (January 1, 2023) requiring pharmaceutical companies to pay financial penalties for injectable drugs which are thrown away with the syringe and not injected into the patient.

Sharps Technology Company Summary

Company Name: Sharps Technology, Inc.

Ticker: STSS

Exchange: NASDAQ

Website: www.sharpstechnology.com

Sharps Technology Company Summary:

Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems.

The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features.

These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use.

Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing.

The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.

Sharps Technology STSS

Sharps Technology has agreed to manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Jan. 10, 2023

Announces the advancement of the Company’s specialized prefillable syringe (“PFS”) system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Braden Miller, Sharps Director of Product Management, commented, “Sharps has developed an alternative high-quality solution to glass syringes through the use of inert polymers such as Cyclic Olefin Polymer (COP) and Cyclic Olefin Copolymer (COC), which offers a high-quality solution compared to traditional glass syringe systems.

These polymer syringes have many of the same characteristics as current pharmaceutical glass designs to support long term drug stability and increase shelf life for customers in the pharmaceutical segment. Polymer syringes can also be made into custom configurations, which can eliminate breakage, minimize dead space, reduce contamination, and support the development of custom devices including autoinjectors.

The ability to produce these innovative products using advanced manufacturing techniques creates additional advantages in the areas of quality, performance and safety when compared to similar glass syringe products. We look forward to introducing this line of next generation products to the market.”

Sharps Technology commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

Dec. 20, 2022

Announced they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary.

The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.

Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry.

These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention.

By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments.

Sharps Technology signed of a distribution agreement with partner Nephron Pharmaceuticals

Dec. 13, 2022

Announced the signing of a distribution agreement with partner Nephron Pharmaceuticals. This is a strategic first step in building the larger partnership between the two companies and is in support of their recently announced collaboration.

“This distribution agreement opens so many possibilities for Sharps Technology and Nephron Pharmaceuticals,” commented Robert Hayes, Sharps Technology CEO. “The timing is perfect in that we are expanding our ability to supply innovative drug delivery systems at a point when the market is in demand for them. Through this distribution plan, Sharps Technology will be able to deliver increased capacity, driving growth for one of the high value product segments of our business.”

  • Each year almost  20 billion injections are administered, globally and the World Health Organization (WHO) are advocating for the use of low waste syringes, with passive safety devices which engage automatically and have auto disable features.

  • STSS anticipates signing its first product orders any moment now this development will represent a huge milestone for this recently debuted NASDAQ company, and should provide them with a solid foundation for growth.

  • The company has raised $16M to scale operations in the coming quarters as they begin to meet the strong and growing demand for smart safety syringes

The global vaccines market is projected to grow from $61.04 billion in 2021 to $125.49 billion in 2028 at a CAGR of 10.8% in the forecast period, 2021-2028.

Vaccines are the most powerful and cost-effective way to protect billions of people in the world, and according to the WHO, immunization awareness and government initiatives have helped prevent 2-3 million deaths a year.

The Covid-19 outbreak led to a shutdown of syringe manufacturing which in turn led to a supply shortage at a global scale.

Mergers and acquisitions of companies such as STSS are highly attractive and are providing the needed innovation to the vaccine market.

The rise in the need for vaccinations and immunizations, plus a surge in the geriatric population, an increase in the number of surgical procedures, as well as a rise in chronic diseases have contributed to a demand for syringes.

Specialty Syringes – Vial Application 

  • Global Smart Syringe Market @ $14 billion USD by 2026 w10.0%+ CAGR 

  • Types: Auto-Disable Syringes and Safety Syringes

  • Applications: Vaccination and Drug Delivery

  • End Users: Hospitals, HMOs and Clinics

  • Target Markets: North America, Europe, and ROW

  • Sharps Technology listed as a supplier

The Pre-Filled Syringe (PFS)/Ready- To- Fill (RTF) syringe product segment will be a priority for the company through its collaboration with Nephron, and is expected to be a gamechanger for the company.

PRE-FILLED SYRINGES MARKET

  • Pre-filled syringes have emerged as one of the fastest-growing choices for unit-dose medication as the pharmaceutical industry seeks new and more convenient drug delivery methods.

  • With PFS/RTF syringes, pharmaceutical companies are able to minimize drug waste and increase product life span, while patients are able to self-administer injectable drugs at their home instead of the hospital.

Ready-To-Use – Pre-Filled Syringes:

  • Types: Plastic and Type I B/S Glass 

  • Applications: Vaccines, Diabetes, Complex High Value Therapies (Gene-Therapy)

  • End Users: Branded Pharma, CMOs, and Biologics

  • Target Markets: North America

There is a growing demand for efficient and easy-to-use drug delivery devices and increasing efforts of healthcare professionals to reduce hospital errors are the principal factors driving the market growth.

STSS announced over the summer that it had completed its acquisition of Safegard Medical’s syringe manufacturing facility in Hungary.

The manufacturing facility is located 2 hours from Budapest (160km from Budapest Airport)

  • 40,000 sq. ft. factory on 250,000 sq. ft. site

  • 20-year history of safety syringe manufacturing

  • FDA registered since 1999

  • ISO 13485 certified

  • CE Mark approved products

  • Injection molding and assembly expertise

  • ETO on-site sterilization capacity

“The acquisition of our first manufacturing facility is an important milestone in our transformation from an R&D-focused enterprise to revenue-generating commercial operations. With the acquisition now complete, with the addition of further assembly and manufacturing capacity, our team is confident we can deliver world-class products to meet the strong and growing demand for smart safety syringes, a market forecasted to reach $14 billion globally by 2026.”

Robert Hayes, CEO of Sharps Technology

IN SUMMARY

Sharps Technology, Inc. (NASDAQ: STSS) is the newest player in the drug delivery device market to go public and could see tremendous blue-sky growth in its future as it continues to ramp up its commercialization efforts.

  • The Company recently announced a significant partnership with Nephron Pharmaceuticals with an anticipated launch into the market in early 2023.

  • STSS anticipates shipping first orders of vial draw product by the beginning of 2023 and ready to fill product in mid-2023 to create initial revenue in 2023 and profits in early 2024.

  • With the global shortage of syringes that comply with the World Health Organization (WHO) requirements, there is a strategic opportunity for STSS to take market share and support the healthcare industry with a better drug delivery platform.

  • The combination of features and benefits for the Sharps products will save lives and eliminate the waste of critically needed medical treatments and therapies for the industry!

  • There’s a key opportunity for STSS to grab a big piece of the market with its proprietary smart safety syringe technology designed to eliminate two million potentially infectious accidental needlestick injuries, as well as billions of dollars in medicine wasted with today’s inefficient syringes with their low-dead space feature.

To reiterate, the company anticipates signing its first distributor agreement during the fourth quarter of 2022, which could be at any moment!

FULL DISCLAIMER

read more
Avalon GloboCare’s (Nasdaq: ALBT) Fusion Gene Map Technology Could Be The Greatest Investment?

Avalon GloboCare’s (Nasdaq: ALBT) Fusion Gene Map Technology Could Be The Greatest Investment?

Jan 9, 2023

Literally, this could be the best investment of the year.

Why, think about this!

Avalon is establishing a leading role in the fields of cellular immunotherapy, exosome technology (ACTEX™), and regenerative therapeutics.

Why is that a big deal?

The global cellular immunotherapy size is expected to reach USD 37.97 billion by 2030!

It is estimated to register a CAGR of 22.41% during the forecast period.

This amazing growth is driven by the growing government support for innovative therapies research, rising prevalence of cancer & development of advanced cell-based immunotherapies.

Now before we get into the top 4 reasons we like ALBT, let’s do a quick summary on the company.

Avalon GloboCare Company Summary

Company Name: Avalon GloboCare Corp.

Ticker: ALBT

Exchange: NASDAQ

Website: www.avalon-globocare.com

Avalon GloboCare Company Summary:

Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services.

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets.

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.

💥 RECESSION PROOF 💥

Historically, what is a great market segment to invest in during a recession, Medical!

In my opinion, The hottest vertical within The Medical market is biotech stocks.

They are safe and recession-proof. 

After all, we can’t stop people from aging or from seeking treatments for a myriad of issues.

Plus, there’s growing demand for innovation in gene therapies, immune-oncology, precision medicine, machine-learning drug discovery, and treatments for unmet medical needs.

According to Grand View Research, the global biotech industry could be worth up to $2.44 trillion by 2028.

The global cellular immunotherapy market size is expected to reach

USD 37.97 billion by 2030!

It is estimated to register a CAGR of 22.41% during the forecast period.

In THREE trading days this stock went up 40%!

Also, it created a base at $4 before it ran 40%!

GUESS WHAT?! It is at $4 again and appears to be ready to run!

Take a look at the buy ratings in #4 Section from Investing.com, Stock.ta and American Bulls!

3 TRUSTED sources saying, “BUY”

Now, let’s look mat what is driving these ratings and explosive gains, the amazing press released by ALBT below.

Jan. 03, 2023

Announced that it has deployed a breakthrough fusion gene map technology to be used for the goal of developing companion diagnostic kits and devices to enhance personalized clinical management of leukemia patients.

In collaboration with the Lu Daopei Institute of Hematology, a fusion gene map database from over 1,000 patients with leukemia was established and the results were previously published in the Blood Cancer Journal. Fusion genes are important genetic abnormalities in leukemia. Using advanced gene sequencing technology, called “Whole Transcriptome Sequencing” (WTS), multiple previously unknown fusion genes were identified which may potentially establish novel diagnostic and therapeutic targets.

Dec. 14, 2022

Announced that the Company completed a private placement of shares of its Series A preferred stock with the Company’s Chairman, Daniel Lu. The gross proceeds of the offering were $4.0 million, which is in addition to the previously announced private placement of $5 million of Series A preferred stock, all of which will be used to pay a portion of the purchase price for the announced acquisition of Laboratory Services MSO, LLC.

As previously announced, the Company’s Series A preferred stock is convertible into shares of the Company’s common stock at price per share equal to the greater of $1.00 or 90% of the closing price of the Company’s common stock on the Nasdaq Stock Market on the day prior to conversion. All holders of the Series A preferred stock will be restricted from selling the shares of common stock issuable upon conversion of the Series A preferred stock for a period of 9 months and will be limited to selling no more than 10% of their shares of common stock in any calendar month.

Sept. 29, 2022

The Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) related to its QTY fusion water-soluble receptor protein platform. The patent was jointly filed with Dr. Shuguang Zhang of the Massachusetts Institute of Technology (MIT) and covers seven claims related to the technology.

ALBT has a 52-week high of $9.40, which is MORE THAN DOUBLE compared to current levels. In fact, it would be upside of 126% if the stock climbs back there.

ALBT even has a STRONG BUY Rating From Highly Respected Investing.com!

ALBT also has a BULLISH sentiment from StockTa.com right now which can be seen HERE.

Additionally, the stock has a STAY LONG rating at AmericanBulls.com which can be seen below:

Currently ALBT boasts a relatively small trading float for a NASDAQ stock at a little over $13M.

Wall Street is still uncovering this hidden gem and with a small number of shares available for trading, a sudden demand could create a major sudden upswing in price. 

Now let’s review the 4 reasons we encourage you to turn your attention to ALBT.

As a quick reminder of the 4 REASONS why you should pull up ALBT right now:

  1. BioTech Market Is Recession Proof

  2. The Chart Looks Like an “Ideal Setup”

  3. The Press Releases are Simply Incredible

  4. Buy Rating Issued from Investing.com

Source 1: https://www.grandviewresearch.com/press-release/global-cellular-immunotherapy-market

Source 2: https://www.grandviewresearch.com/industry-analysis/cellular-immunotherapy-market-

FULL DISCLAIMER

read more
Clearmind Medicine Inc. (Nasdaq: CMND) Is Disrupting The Pharmaceutical Industry with a Revolutionary Treatment!

Clearmind Medicine Inc. (Nasdaq: CMND) Is Disrupting The Pharmaceutical Industry with a Revolutionary Treatment!

Jan 4, 2023

Clearmind Medicine CMND has consolidated from the latest amazing 252% run & indicators appear to reveal more explosive gains in the near future!

Now that it has created a base it appears ready for it’s next HUGE run, could it be 600%, 700%, 1,000%?!?!

Let’s take a quick look at the basics before digging into why CMND could be ready for it’s next big move!

Clearmind Medicine Company Summary

Company Name: Clearmind Medicine, Inc.

Ticker: CMND

Exchange: NASDAQ

Website: https://www.clearmindmedicine.com/

Clearmind Medicine Company Summary:

Clearmind Medicine Inc. (Nasdaq: CMND) is a psych-e-delic pharmaceutical biotech company focused on the discovery and development of novel psych-e-delic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.

Its primary objective is to research and develop psych-e-delic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of seven patent families.

Clearmind Medicine Inc. (Nasdaq: CMND) intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Clearmind’s flagship treatments are focused on Alcohol Use Disorder(AUD), which is incredibly common. It varies from mild to excessive, and describes a person’s inability to restrict their alcohol consumption, despite negative social, occupational, or health consequences.

Clearmind Medicine Inc. Scores Milestone Patent 

Dec 27, 2022

Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) has taken a giant step forward in its mission to deliver a first-to-market psychedelic-based treatment targeting Alcohol Use Disorder (AUD). Last Wednesday, CMND announced being granted a patent from the United States Patent and Trademark Office (USPTO) to use its proprietary MEAI as an alcoholic beverage substitute. This allowance strengthens an already robust IP portfolio by adding to similar patents earned for its MEAI-based alcohol substitute in Europe and India.

The full article can be found HERE

Clearmind Medicine Inc.’s Psychedelic-Based Therapeutics Are Revolutionary To The Pharmaceutical Sector; Treating AUD In The Crosshairs ($CMND)

January 3rd, 2023

Driving that proposition is Clearmind Medicine nearing its goal of delivering a first-to-market psychedelic-based treatment to market, with its lead candidate, MEAI, targeting a $395BN alcohol-substitute product market.

“In pre-clinical trials, showed an ability to mitigate AUD Alcohol Use Disorder: a condition that encourages a vicious cycle of binge drinking by circumventing specific neural pathways that lead to sensible behavioral decisions. “

The full article can be found HERE

Clearmind Medicine Inc. Positions To Deliver A First-To-Market Psychedelic-Based Treatment For Alcohol Use Disorder

Dec 29, 2022

Thanks to a series of milestones reached, patents earned, and valuable partnerships, the company’s lead candidate, MEAI, may soon become the first-to-market psychedelic-based treatment targeting Alcohol Use Disorder (AUD). As an alcohol-substitute product, MEAI positions Clearmind to target a more than $395 million alcohol-substitute market opportunity and, more importantly, provide a product that could save millions of lives each year.

The full article can be found HERE

There is a massive market potential for Clearmind Medicine Inc. (Nasdaq: CMND). The company focuses on a huge untapped market with yearly economic impact costing the U.S. over $249 billion.(1)

Clearmind Medicine Inc. (Nasdaq: CMND) currently has 8 patents granted with 15 patent applications pending.(1) A patent can be an economic catalyst to pharmaceutical companies who push to research new and beneficial drugs on the premise that they will be able to reap rewards by way of profits.(2)

According to a national survey, 14.1 million adults ages 18 and older (5.6 percent of this age group) had AUD in 2019. (3)

Among youth, an estimated 414,000 adolescents ages 12–17 (1.7 percent of this age group) had AUD during this timeframe.(3)

What Increases the Risk for AUD? A person’s risk for developing AUD depends, in part, on how much, how often, and how quickly they consume alcohol. (3)

Alcohol misuse, which includes binge drinking and heavy alcohol use, over time increases the risk of AUD.(3)

Other factors also increase the risk of AUD, such as:

  • Drinking at an early age. A recent national survey found that among people ages 26 and older, those who began drinking before age 15 were more than 5 times as likely to report having AUD in the past year as those who waited until age 21 or later to begin drinking. The risk for females in this group is higher than that of males. (3)

  • Genetics and family history of alcohol problems. Genetics play a role, with heritability approximately 60 percent; however, like other chronic health conditions, AUD risk is influenced by the interplay between a person’s genes and their environment. Parents’ drinking patterns may also influence the likelihood that a child will one day develop AUD.(3)

  • Mental health conditions and a history of trauma. A wide range of psychiatric conditions—including depression, post-traumatic stress disorder, and attention deficit hyperactivity disorder—are comorbid with AUD and are associated with an increased risk of AUD. People with a history of childhood trauma are also vulnerable to AUD.(3)

Breaking the Cycle
Clearmind Medicine Inc. (Nasdaq: CMND) believes that MEAI breaks the vicious binge-drinking cycle at the decision point to drink more alcohol,by potentially innervating neural pathways such as 5-HT1A that lead to “sensible behavior.”(6)

Non-Addictive
Anecdotal reports and pre-clinical in-vivo results indicate on the self-limiting property of MEAI—unlike traditional treatments.(6)

Expansive Potential
The literature shows that 5-HT1A receptors are associated with controlling craving behavior across the board. This indicates that MEAI may have a wide range of applications beyond binge drinking.(6)

Successful preclinical results in MEAI treatment for alcohol consumption.(6)

Clearmind Medical is advancing its proprietary CMND-100, 5-methoxy-2-aminoindane-based treatment (MEAI), intending to provide relief to millions worldwide by using psychedelics to treat Alcohol Use Disorder (AUD).

The market potential from an approved CMND therapeutic can be enormous, replacing drugs and treatments that are sometimes more debilitating than the condition itself.

More importantly, CMND’s approach could mitigate patient resistance to treatment, opening the door to potentially billions in long-term revenues and saving thousands of lives per year. 

Biotech and Pharmaceutical stocks can offer tremendous upside potential when positive news is announced from Phase 1, Phase 2, and Phase 3 trials. Clearmind Medicine Inc. (Nasdaq: CMND) recently announced the initiation of a program to address its upcoming clinical trial.(4)

Clearmind Medicine Inc. recently announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100.(4)

The produced batches will be used in the Company’s upcoming first in human (FIH) clinical trial evaluating the proprietary drug candidate compound CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Following MEAI’s synthesis development process, the compound is being produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.

The clinical batches production is made possible due to prior successful production of MEAI drug substance that was used in the Company’s pre- clinical studies designed to evaluate the safety of its innovative compound.

“Clearmind continues its progress toward FIH clinical trials,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.

“This milestone joins other achievements we’ve made in a relatively short period. Non-clinical data generated to date, demonstrate that our MEAI- based treatment has the potential to treat broad range of addictions and binge behaviors such as AUD.”(4)

“Like other addictions, AUD is a chronic relapsing brain disorder characterized by an impaired ability to stop or control alcohol use,” she added. (4)

“Alcohol abuse is the third most-common preventable cause of death in the United States, where almost 6% struggle with this condition.”(4)

The Company previously announced that it completed a highly constructive Pre-Investigational New Drug Application (“pre-IND”) meeting with the U.S. Food and Drug Administration (“FDA”) to discuss the development of CMND-100.

Clearmind Medicine Inc. (Nasdaq: CMND) has less than 1.2M shares available in its public float according to Finviz.(5) Low float stocks have the potential to present significant price swings if active market participants take notice.

Short squeeze?

If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme. Low float stocks can be some of the most volatile stocks in the market.

Clearmind Medicine CMND has consolidated from the latest amazing 252% run & indicators appear to reveal more explosive gains in the near future! Let’s review the 4 reasons you should put it on you watchlist NOW.

As a quick reminder of the 4 REASONS why you should pull up KAVL right now:

  1. Incredible Press Releases announcing their US Patent!

  2. Untapped Market Worth $249BN

  3. Clinical Trials on the horizon that could be worth Bill-ions

  4. Extremely Low Float – 1.2M shares is stupid LOW!

Source 1: https://www.clearmindmedicine.com/investors

Source 2: https://www.mckendree.edu/academics/scholars/issue11/bodem.htm

Source 3: https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/understanding-alcohol-use-disorder

Source 4: https://finance.yahoo.com/news/clearmind-announces-initiation-cmnd-100-134500937.html

Source 5: https://finviz.com/quote.ashx?t=CMND&p=d

Source 6: https://www.clearmindmedicine.com/investors

FULL DISCLAIMER

read more

Kaival Brands Innovations (NASDAQ:KAVL) Has 200% upside, buy rating, killer news & is trading at $1.00!

Dec 6, 2022

Kaival Brands KAVL has been reversing from the latest amazing 482% RUN!

Now, it has created a base and appears to be ready for it’s next HUGE run, could it be 600%, 700%, 1,000%?!?!

Let’s take a quick look at the basics before digging into why KAVL could be ready for it’s next big move!

Kaival Brands KAVL Company Summary

Company Name: Kaival Brands Innovations Group, Inc.

Ticker: KAVL

Exchange: NASDAQ

Website: www.ir.kaivalbrands.com.

Kaival Brands Company Summary:

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets.

Our vision is to develop internally, acquire, own, or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor.

Yahoo Finance and MarketWatch have issued BUY Ratings.

Yahoo Finance Short Term Indicators are:

Short Term KST Indicator: Short-term KST. Short-term KST. Implication. A bullish signal is generated when the KST, “Know Sure Thing“, rises above its moving average. When the KST falls below its moving average, the Technical Event® is a bearish signal.

“This is closest to a guarantee in the trading indicator category, so you can have a little peace of mind.” Alexander Goldman

RSI: The Relative Strength Index (RSI), developed by J. Welles Wilder, is a momentum oscillator that measures the speed and change of price movements. The RSI oscillates between zero and 100. Traditionally the RSI is considered overbought when above 70 and oversold when below 30.

Moving average convergence divergence (MACD): Moving average convergence/divergence (MACD, or MAC-D) is a trend-following momentum indicator that shows the relationship between two exponential moving

MarketWatch Rating

Buy: A classic BUY signal on Market Watch

You will be able to see why Yahoo and Marketwatch has issued Buy Ratings, take a look below and it is clear as day!

But before, Take a minute and think about this, KAVL is up 32% in 2022!

WOWZERS

Take a look at the 1 year chart below, almost up 100% from January 27th.

As you can see the support has been amazing for the last 5 months around the $1 PPS. I am very confident that there is very little downside and TONS of upside with KAVL based on this chart.

Also, you can see an event looming in the technicals pushing this higher coming very soon.

The squeezing affect of higher bottoms and lower highs until BOOM it breaks out and runs!

I believe the chart is revealing a big move coming!

Also YAHOOFINANCE and MARKETWATCH agrees! BUY RATINGS

I have reviewed countless research reports and press releases and the one below really sums up the true potential in KAVL the best!

“Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) stock may be trading over 41% higher since the start of the year, but considering its position to capitalize upon and maximize a billion-dollar opportunity within the electronic nicotine delivery system market, that impressive gain is likely the precursor of an even more significant move to come.

That bullish presumption isn’t made on blind faith; it’s a result of a vastly changed competitive landscape in the ENDS market that has left KAVL as one of the few companies left standing able to sell ENDS products into a massive U.S. market.”

FULL ARITCLE

As a quick reminder of the 3 REASONS why you should pull up KAVL right now:

  1. Analyst & Indicators have issued a buyers rating – MarketWatch and Yahoo Finance love KAVL and you should too!

  2. Up 32% YTD and the chart looks like it is about to explode again! The base is so obvious and it has absolute monster runs and we believe they are about to go on another one again!

  3. A joint venture with KAVL and Philip Morris, absolutely transformative NEWS!

FULL DISCLAIMER

read more

LOW Float LuxUrban Hotels (NASDAQ:LUXH) Has 124% upside & is trading under $2, NOT FOR LONG!

Nov 30, 2022

LuxUrban Hotels (NASDAQ:LUXH) could be a little missile and trading under $1.50 and positioned to soar like a eagle with just the slightest volume. We could see $2.00+++ tomorrow with modest volume!

Think about this:

Higher LOWS +
Low Float +
Bouncing Off Incredible Support and Creating A New Higher BASE +
Walking into the vacation season, ONE of the busiest seasons of the YEAR!

= EXPLOSIVE POTENTIAL GAINS COME EARLY FOR CHRISTMAS

Let’s take a close look at the top 3 catalysts that could ignite this missle!

I can’t stress this enough, this is low float is a HUGE cataylst! 

TWO points we would like to make!

#1

4.4 Million shares in the float is TINY! That is a little over $6M in total volume to trade the whole float in a day! That is not out of the realm of possibility for tomorrow!

#2

LUXH ONLY trades 55,000 shares daily! That is $70,000 +/-!

Are you kidding me? Lux will trade that in the first 30 minutes tomorrow!

What does that mean? Hmmmm… We will SEE!

I do predict, a massive spike in volume and a potential rocket ship in price per share!

Christmas could be tomorrow for our subscribers!

Record Quarterly Net Rental Revenue of $11.6 Million
Significant Increases in Gross Profit, RevPAR, and Occupancy Rates

Adjusted Net Income of $0.6 Million Excludes $4.6 Million of Non-Cash and One-Time Expenses
Adjusted EBITDA Rose to $2.4 Million

Reiterates Annual Guidance for 2022 and 2023

MIAMI, November 14, 2022–(BUSINESS WIRE)–LuxUrban Hotels Inc. (or the “Company”) (Nasdaq: LUXH), which utilizes a long-term lease, asset-light business model to acquire and manage a growing portfolio of short-term rental properties in major metropolitan cities, today announced financial results for the third quarter (“Q3 2022”) and nine months ended September 30, 2022.

2022 Third Quarter Financial Overview Compared to 2021 Third Quarter

  • Net rental revenue rose 74.2% to $11.6 million from $6.6 million
  • Gross profit improved to $4.9 million, or 42.2% of net rental revenue, from $0.8 million, or 11.9% of net rental revenue
  • Net loss of $3.2 million, or $(0.13) per share, was primarily impacted by a one-time, non-cash $2.4 million warrant expense and a one-time cash expense of $1.8 million related to the Company’s planned exit from its legacy apartment rental business as part of its rebranding initiatives; net loss in Q3 2021, which did not include these expenses, was less than $0.1 million
  • Adjusted net income (a non-GAAP measure; see reconciliation tables in this press release) improved to $0.6 million, or $0.03 per share, from a net loss of less than $0.1 million
  • Adjusted EBITDA (a non-GAAP measure; see reconciliation tables in this press release) increased to $2.4 million from $0.5 million

Operational Highlights

  • For the 2022 nine-month period, RevPAR rose 30% to $149 from $115, and occupancy rates improved to 87% from 71%
  • Currently operate approximately 1,200 short term hotel rental units, which have been fully funded
  • Expect to operate a total of approximately 1,500 short term hotel rental units by or around December 31, 2022, with no outside funding required for the additional 300 units
  • Launched corporate rebranding initiative
  • Implemented initiatives to expand margins, generate positive cash flows, and drive profitability

“Our performance in Q3 2022 validated the growth, sustainability, and predictability of our operating model,” said Brian Ferdinand, Chairman and Chief Executive Officer. “We recorded the highest quarterly net revenue in our history, expanded our operating portfolio of short-term rental hotel units, and grew RevPAR and occupancy rates across the portfolio. Excluding the one-time, non-cash warrant expense charges and one-time costs associated with our planned exit from our legacy apartment rental business, adjusted net income improved to $0.6 million and adjusted EBITDA rose 348%, respectively, from last year’s third quarter.

“We are confident in the trajectory of our business and excited about our performance through the first nine months of the year, reporting net rental revenue of $30.9 million, adjusted net income of $3.5 million, EBITDA of $4.3 million, and adjusted EBITDA of $6.5 million. As such, we are pleased to reiterate our full year 2022 and 2023 net revenue and EBITDA guidance.”

He concluded, “As a complement to anticipated net revenue growth, we have commenced initiatives designed to expand margins, generate positive cash flows, and drive profitability. This includes our agreement with Rebel Hotel Company, which we estimate will deliver margin enhancements that we would not have been able to realize until at least 2024, and our recently announced agreement with a new credit card processing company that eliminates the need for reserves and reduces associated processing expenses by approximately 400 bps compared to our former processor relationships. As a result of this new relationship, our former credit card processors will release to the Company approximately $5.5 million in reserves over the next 12 months.”

If I had a microphone I would DROP IT!

Stevie Wonder could see the potential!

I’m out of jokes, just go pull up LUXH right NOW because we have enough REGRET, we don’t need anymore!

DISCLAIMER:

Small Cap Exclusive is owned and operated by JBN PARTNERS LLC, which is a US based corporation has NOT been compensated for profiling LUXH. We own ZERO shares in LUXH.

We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (this “Article”) about publicly traded companies (the “Profiled Issuers”).

FULL DISCLAIMER

read more

DOCU DocuSign, Inc Stock Price Is Undervalued!

Sep 17, 2022

DocuSign DOCU was trading at almost $400 a year ago, now it’s at $56. This is an incredible value and we love it!

Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!


[thrive_leads id=’14274′]

DocuSign Inc. Company Information

Company Name: DocuSign

Ticker: DOCU

Exchange: NASDAQ

Website: www.docusign.com

DOCUSIGN Company Summary:

DocuSign helps organizations connect and automate how they prepare, sign, act on, and manage agreements. As part of the DocuSign Agreement Cloud, DocuSign offers eSignature, the world’s #1 way to sign electronically on practically any device, from almost anywhere, at any time. Today, over 1.2 million customers and more than a billion users in over 180 countries use the DocuSign Agreement Cloud to accelerate the process of doing business and simplify people’s lives.

DocuSign stock price is due to News?

Sept. 8, 2022 /PRNewswire/ — DocuSign, Inc. (NASDAQ: DOCU), which offers the world’s #1 e-signature solution as part of the DocuSign agreement platform, today announced results for its fiscal quarter ended July 31, 2022.

DocuSign, Inc. (PRNewsFoto/DocuSign, Inc.)
DocuSign, Inc. (PRNewsFoto/DocuSign, Inc.)

“We delivered solid Q2 results, with a strong finish to the first half of the year. These results reflect the focus and dedication of our team on execution during this transition period, with a stronger foundation in place to deliver in the second half of the year. We enter this next phase with a clear set of vital few deliverables for our people initiatives and product roadmap, while driving sustainable and profitable growth at scale,” said Maggie Wilderotter, DocuSign’s Interim CEO and Board Chair. “We have a $50 billion market opportunity, an industry leading digital agreement platform, strong market position, and an experienced leadership team. I have total confidence our team will successfully deliver for all stakeholders.”

Second Quarter Financial Highlights

  • Total revenue was $622.2 million, an increase of 22% year-over-year. Subscription revenue was $605.2 million, an increase of 23% year-over-year. Professional services and other revenue was $17.0 million, a decrease of 11% year-over-year.
     
  • Billings were $647.7 million, an increase of 9% year-over-year.
     
  • GAAP gross margin was 78% for both periods. Non-GAAP gross margin was 82% for both periods.
     
  • GAAP net loss per basic and diluted share was $0.22 on 201 million shares outstanding compared to $0.13 on 196 million shares outstanding in the same period last year.
     
  • Non-GAAP net income per diluted share was $0.44 on 206 million shares outstanding compared to $0.47 on 208 million shares outstanding in the same period last year.
     
  • Net cash provided by operating activities was $120.9 million compared to $177.7 million in the same period last year.
     
  • Free cash flow was $105.5 million compared to $161.7 million in the same period last year.
     
  • Cash, cash equivalents, restricted cash and investments were $1,129.6 million at the end of the quarter.

A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures and Other Key Metrics.”

Operational and Other Financial Highlights

DocuSign Agreement Cloud 2022 Product Release 2. DocuSign announced new product capabilities, including:

  • DocuSign eSignature. Introduced Shared Access, which allows a user to be granted permission to send or manage envelopes on another user’s behalf, and announced enhancements to Bulk Send and Agreement Actions.
  • DocuSign eSignature App for Stripe. A new integration that allows account, finance and support teams to view eSignature agreements and Stripe payments side-by-side and launch new agreements right from their Stripe dashboards. Stripe users no longer need to go between the two platforms to complete transactions, support customers, or review transactions.
  • DocuSign CLM. Introduced a new CLM Integration within Slack that enables customers to collaborate and move their agreements forward in a more streamlined way. CLM for Slack allows users to navigate the full agreement processes from redlining, to reviews and approvals, using our leading CLM solution without ever leaving the Slack platform. Other CLM enhancements include CLM AI-assisted data capture and a new integration with DocuSign CLM Connector for Coupa.
  • DocuSign Notary. Introduced support for notaries seated in two additional U.S. states, New Jersey and Oregon, bringing the total number of states supported by DocuSign Notary to 25.

Outlook

The company currently expects the following guidance:

•     Quarter ending October 31, 2022 (in millions, except percentages):
Total revenue $624 to $628
Subscription revenue $609 to $613
Billings $584 to $594
Non-GAAP gross margin 79 % to 81 %
Non-GAAP operating margin 16 % to 18 %
Non-GAAP diluted weighted-average shares outstanding 205 to 210

•     Year ending January 31, 2023 (in millions, except percentages):
Total revenue $2,470 to $2,482
Subscription revenue $2,405 to $2,417
Billings $2,550 to $2,570
Non-GAAP gross margin 79 % to 81 %
Non-GAAP operating margin 16 % to 18 %
Non-GAAP diluted weighted-average shares outstanding 205 to 210

The company has not reconciled its guidance of non-GAAP financial measures to the corresponding GAAP measures because stock-based compensation expense cannot be reasonably calculated or predicted at this time. Accordingly, a reconciliation has not been provided.

DOCU 5 Day Chart

Breakout Alert!

Docusign is the 500LB gorilla in the electronic document signing vertical and that is not changing anytime soon. The stock is undervalued and took a beating with all other stocks in the massive sell off of 2022. Look for a massive bounce!


[thrive_leads id=’14274′]

read more

(NASDAQ-SNDL) A Cannabis Stock Announces Intl Export!

Sep 17, 2022

On Wednesday September 14th SNDL Inc. (SNDL) a Cannabis Stock went Up due to the announcement of an in international export deal with Israel. However, it quickly fell through support. Was it a head fake? Is it the bottom and it’s ready to bounce? Keep reading to find out.

Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!


[thrive_leads id=’14274′]

SNDL Inc. Company Information

Company Name: SNDL Inc.

Ticker: SNDL

Exchange: NASDAQ

Website: https://www.sndl.com/

Sundial Company Summary:

SNDL is the largest private sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. SNDL is a licensed cannabis producer that uses state-of-the-art indoor facilities to supply wholesale and retail customers under a cannabis brand portfolio that includes Top Leaf, Sundial Cannabis, Palmetto, Spiritleaf Selects, and Grasslands. SNDL’s investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the global cannabis industry.

Sundial stock price is due to News?

Sept. 15, 2022 

Today announced that SNDL has completed its initial international export of approximately 167 kilograms of premium dried flower from Canada to Israel as part of its total commitment with IMC. SNDL and IMC have agreed to the aggregate export of 1,000 kilograms of high-quality dried flower products for processing and distribution in the Israeli medical cannabis market.

IM Cannabis Logo
IM Cannabis Logo

The expansion marks a significant milestone for SNDL as it enters the global market. “We are pleased with our partnership with IMC, one of Europe’s most established and trusted medical cannabis companies,” said Andrew Stordeur, President and Chief Operating Officer of SNDL. “SNDL plans to opportunistically expand the Company’s premium inhalables footprint to international cannabis markets, and this initial endeavour strengthens our pursuits in both established medical markets and emerging global recreational markets.”

For IMC, the completed export marks another major step forward in streamlining its expansive global operations that include Israel, Canada, and Germany. “The medical cannabis market in Israel has shifted towards premium and ultra-premium cannabis products. By forming an international partnership with SNDL, we are improving our global supply chain and enhancing our ability to provide the Israeli market with the high-quality products it has come to expect,” said Oren Shuster, Chief Executive Officer of IM Cannabis.

SNDL views the international market as an emerging opportunity to increase revenue from its cannabis operations. The Company is optimistic that an increasing number of global markets will refine regulations, allowing for lower-barrier access to high-quality cannabis products produced by trusted suppliers from Canada.

SNDL 5 Day Chart

#1 Cannabis PLAY!

The announcement Todaythat SNDL has completed its initial international export of approximately 167 kilograms of premium dried flower from Canada to Israel as part of its total commitment with IMC is a groundbreaking deal for the cannabis industry and for SNDL.


[thrive_leads id=’14274′]

read more

(NASDAQ-OPEN) Stock Price Is Ready To Bounce?

Sep 17, 2022

On Monday September 12th Ilustrato Open Door Technologies (NASDAQ-OPEN) Stock Price went Up BIG and broke through a serious resistance point. However, it quickly fell through support. Was it a head fake? Is it the bottom and it’s ready to bounce? Keep reading to find out.

Before we do, remember to stop what you are doing and 👇 Sign up for our newsletter to get the latest breakout stocks and trending stocks!


[thrive_leads id=’14274′]

Open Door Technologies Company Information

Company Name: Open Door Technologies

Ticker: OPEN

Exchange: NASDAQ

Website: https://investor.opendoor.com.

Ilustrato Pictures Company Summary:

Selling a home can be full of uncertainty for many consumers who would rather focus on their next chapter than on the stresses of moving. Potential sellers on Zillow apps and sites may request and view an offer directly from Opendoor and easily compare it to an open-market sale using a real estate agent.

OPEN stock price is due to News?

Aug. 4, 2022

Zillow, Inc. (Nasdaq: Z and ZG) and Opendoor Technologies Inc. (Nasdaq: OPEN) have announced a multi-year partnership that combines two category leaders to transform how people start their move. The partnership will allow home sellers on the Zillow platform to seamlessly request an Opendoor offer to sell their home.

Zillow logo (PRNewsfoto/Zillow Group)
Zillow logo (PRNewsfoto/Zillow Group)

Selling a home can be full of uncertainty for many consumers who would rather focus on their next chapter than on the stresses of moving. Potential sellers on Zillow apps and sites may request and view an offer directly from Opendoor and easily compare it to an open-market sale using a real estate agent. Opendoor offers will be available on Zillow, and customers will be able to use the service as a standalone offering or package it with other Zillow home shopping services such as financing, closing and agent selection. Additionally, Zillow customers will be able to work with a licensed Zillow advisor who will serve as a helpful guide in understanding these options.

“Zillow is the most visited brand in online real estate. As we bring the housing super app to life, we’re empowering our millions of visitors to understand all their options and transact in the way that best meets their housing needs,” said Zillow Chief Operating Officer, Jeremy Wacksman. “We know choice is important for customers and they can make the best decision when they see all of their selling options up front — including selling on the open market with a Zillow Premier Agent partner and getting a cash offer from Opendoor. This exclusive partnership will pair Zillow’s audience and brand power with Opendoor’s selling solution in one easy place, so customers can evaluate their selling options and easily package it with other Zillow services to buy and finance their next home.”

OPEN 5 Day Chart

Bounce Play, I think so, here is why!

OPEN is the amazon for real estate tech companies and it has been oversold and is greatly undervalued! I am excited for the future of this real estate darling and you should be too!


[thrive_leads id=’14274′]

read more